Safety of vaccination against SARS-CoV-2 ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry.
Auteur(s) :
Machado, Pedro M. [Auteur]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Lawson-Tovey, Saskia [Auteur]
Manchester University NHS Foundation Trust [MFT]
Strangfeld, Anja [Auteur]
Deutsches Rheuma-ForschungsZentrum [DRFZ]
Mateus, Elsa F. [Auteur]
Hyrich, Kimme L. [Auteur]
Manchester University NHS Foundation Trust [MFT]
Gossec, Laure [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Carmona, Loreto [Auteur]
Instituto de Salud Musculoesqueletica [InMusc]
Rodrigues, Ana [Auteur]
NOVA Medical School - Faculdade de Ciências Médicas [NMS]
Raffeiner, Bernd [Auteur]
Duarte, Catia [Auteur]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Veillard, Eric [Auteur]
Strakova, Eva [Auteur]
University of Prešov
Burmester, Gerd R. [Auteur]
Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
Yardımcı, Gözde Kübra [Auteur]
Faculty of Medicine [Hacettepe University]
Gomez-Puerta, Jose A. [Auteur]
University of Barcelona
Zepa, Julija [Auteur]
Riga Stradins University [RSU]
Kearsley-Fleet, Lianne [Auteur]
University of Manchester [Manchester]
Trefond, Ludovic [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Cunha, Maria [Auteur]
Mosca, Marta [Auteur]
University of Pisa - Università di Pisa
Cornalba, Martina [Auteur]
Soubrier, Martin [Auteur]
CHU Gabriel Montpied [Clermont-Ferrand]
Roux, Nicolas [Auteur]
Brocq, Olivier [Auteur]
Hôpital Princesse Grace [Monaco]
Durez, Patrick [Auteur]
Cliniques Universitaires Saint-Luc [Bruxelles]
Conway, Richard [Auteur]
St James's University Hospital
Goulenok, Tiphaine [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Bijlsma, Johannes W. [Auteur]
Universiteit Utrecht / Utrecht University [Utrecht]
Mcinnes, Iain B. [Auteur]
University of Glasgow
Mariette, Xavier [Auteur]
Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes [IMVA-HB]
University College London Hospitals NHS Foundation Trust [London, UK] [UCLH]
Lawson-Tovey, Saskia [Auteur]
Manchester University NHS Foundation Trust [MFT]
Strangfeld, Anja [Auteur]
Deutsches Rheuma-ForschungsZentrum [DRFZ]
Mateus, Elsa F. [Auteur]
Hyrich, Kimme L. [Auteur]
Manchester University NHS Foundation Trust [MFT]
Gossec, Laure [Auteur]
Institut Pierre Louis d'Epidémiologie et de Santé Publique [iPLESP]
Carmona, Loreto [Auteur]
Instituto de Salud Musculoesqueletica [InMusc]
Rodrigues, Ana [Auteur]
NOVA Medical School - Faculdade de Ciências Médicas [NMS]
Raffeiner, Bernd [Auteur]
Duarte, Catia [Auteur]
Hachulla, Eric [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Veillard, Eric [Auteur]
Strakova, Eva [Auteur]
University of Prešov
Burmester, Gerd R. [Auteur]
Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
Yardımcı, Gözde Kübra [Auteur]
Faculty of Medicine [Hacettepe University]
Gomez-Puerta, Jose A. [Auteur]
University of Barcelona
Zepa, Julija [Auteur]
Riga Stradins University [RSU]
Kearsley-Fleet, Lianne [Auteur]
University of Manchester [Manchester]
Trefond, Ludovic [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Cunha, Maria [Auteur]
Mosca, Marta [Auteur]
University of Pisa - Università di Pisa
Cornalba, Martina [Auteur]
Soubrier, Martin [Auteur]
CHU Gabriel Montpied [Clermont-Ferrand]
Roux, Nicolas [Auteur]
Brocq, Olivier [Auteur]
Hôpital Princesse Grace [Monaco]
Durez, Patrick [Auteur]
Cliniques Universitaires Saint-Luc [Bruxelles]
Conway, Richard [Auteur]
St James's University Hospital
Goulenok, Tiphaine [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Bijlsma, Johannes W. [Auteur]
Universiteit Utrecht / Utrecht University [Utrecht]
Mcinnes, Iain B. [Auteur]
University of Glasgow
Mariette, Xavier [Auteur]
Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes [IMVA-HB]
Titre de la revue :
Annals of the Rheumatic Diseases
Nom court de la revue :
Ann Rheum Dis
Date de publication :
2022-01-04
ISSN :
1468-2060
Mot(s)-clé(s) en anglais :
COVID-19
vaccination
autoimmune diseases
antirheumatic agents
epidemiology
vaccination
autoimmune diseases
antirheumatic agents
epidemiology
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Objectives To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD).
Methods Physician-reported registry of I-RMD and non-inflammatory ...
Lire la suite >Objectives To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, RMD diagnosis, disease activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) and SARS-CoV-2 breakthrough infections. Data were analysed descriptively. Results The study included 5121 participants from 30 countries, 90% with I-RMDs (n=4604, 68% female, mean age 60.5 years) and 10% with NI-RMDs (n=517, 77% female, mean age 71.4). Inflammatory joint diseases (58%), connective tissue diseases (18%) and vasculitis (12%) were the most frequent diagnostic groups; 54% received conventional synthetic disease-modifying antirheumatic drugs (DMARDs), 42% biological DMARDs and 35% immunosuppressants. Most patients received the Pfizer/BioNTech vaccine (70%), 17% AstraZeneca/Oxford and 8% Moderna. In fully vaccinated cases, breakthrough infections were reported in 0.7% of I-RMD patients and 1.1% of NI-RMD patients. I-RMD flares were reported in 4.4% of cases (0.6% severe), 1.5% resulting in medication changes. AEs were reported in 37% of cases (37% I-RMD, 40% NI-RMD), serious AEs in 0.5% (0.4% I-RMD, 1.9% NI-RMD). Conclusion The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.Lire moins >
Lire la suite >Objectives To describe the safety of vaccines against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD). Methods Physician-reported registry of I-RMD and non-inflammatory RMD (NI-RMDs) patients vaccinated against SARS-CoV-2. From 5 February 2021 to 27 July 2021, we collected data on demographics, vaccination, RMD diagnosis, disease activity, immunomodulatory/immunosuppressive treatments, flares, adverse events (AEs) and SARS-CoV-2 breakthrough infections. Data were analysed descriptively. Results The study included 5121 participants from 30 countries, 90% with I-RMDs (n=4604, 68% female, mean age 60.5 years) and 10% with NI-RMDs (n=517, 77% female, mean age 71.4). Inflammatory joint diseases (58%), connective tissue diseases (18%) and vasculitis (12%) were the most frequent diagnostic groups; 54% received conventional synthetic disease-modifying antirheumatic drugs (DMARDs), 42% biological DMARDs and 35% immunosuppressants. Most patients received the Pfizer/BioNTech vaccine (70%), 17% AstraZeneca/Oxford and 8% Moderna. In fully vaccinated cases, breakthrough infections were reported in 0.7% of I-RMD patients and 1.1% of NI-RMD patients. I-RMD flares were reported in 4.4% of cases (0.6% severe), 1.5% resulting in medication changes. AEs were reported in 37% of cases (37% I-RMD, 40% NI-RMD), serious AEs in 0.5% (0.4% I-RMD, 1.9% NI-RMD). Conclusion The safety profiles of SARS-CoV-2 vaccines in patients with I-RMD was reassuring and comparable with patients with NI-RMDs. The majority of patients tolerated their vaccination well with rare reports of I-RMD flare and very rare reports of serious AEs. These findings should provide reassurance to rheumatologists and vaccine recipients and promote confidence in SARS-CoV-2 vaccine safety in I-RMD patients.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-12T05:19:58Z
2024-02-06T08:28:46Z
2024-02-06T08:28:46Z